(Q34063686)

30 July 2017

title

Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture (English)

1 reference

30 July 2017

0 references

1 reference

Colón-Emeric C

1

1 reference

30 July 2017

Yballe L

2

1 reference

30 July 2017

Sloane R

3

1 reference

30 July 2017

Pieper CF

4

1 reference

30 July 2017

Lyles KW

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

Journal of the American Geriatrics Society

30 July 2017

published in

1 reference

30 July 2017

volume

48

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1261-1263

1 reference

Decline in physical function following hip fracture

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Mobility after hip fracture predicts health outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Severe Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Pathogenesis of vertebral crush fractures in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Prescribing by general practitioners after an osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB02599.X

10.1111/J.1532-5415.2000.TB02599.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference